Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eton Pharmaceuticals (ETON) EBIT Margin (2019 - 2025)

Eton Pharmaceuticals' EBIT Margin history spans 7 years, with the latest figure at 11.05% for Q4 2025.

  • On a quarterly basis, EBIT Margin fell 978.0% to 11.05% in Q4 2025 year-over-year; TTM through Dec 2025 was 1.48%, a 57.0% increase, with the full-year FY2025 number at 1.2%, up 85.0% from a year prior.
  • EBIT Margin hit 11.05% in Q4 2025 for Eton Pharmaceuticals, up from 6.07% in the prior quarter.
  • Over the last five years, EBIT Margin for ETON hit a ceiling of 87.41% in Q4 2022 and a floor of 754.45% in Q3 2021.
  • Historically, EBIT Margin has averaged 55.12% across 5 years, with a median of 7.8% in 2023.
  • The widest YoY moves for EBIT Margin: up 2261419bps in 2021, down -24731177bps in 2021.
  • Tracing ETON's EBIT Margin over 5 years: stood at 21.57% in 2021, then skyrocketed by 305bps to 87.41% in 2022, then tumbled by -108bps to 6.69% in 2023, then skyrocketed by 411bps to 20.83% in 2024, then crashed by -47bps to 11.05% in 2025.
  • Business Quant data shows EBIT Margin for ETON at 11.05% in Q4 2025, 6.07% in Q3 2025, and 7.79% in Q2 2025.